One Shot to Smarter? Psychedelic Drug DOI Boosts Cognitive Flexibility in Mice

Forum topic · ✨步子哥 · 2026-01-04

Summary

Researchers at Weill Cornell Medicine, including Merima Šabanović, found that a single dose of DOI (2,5-dimethoxy-4-iodoamphetamine), a synthetic psychedelic, can produce lasting structural changes in mouse brains and significantly improve cognitive flexibility. Published in Nature Molecular Psychiatry, the study shows the drug activates serotonin receptors and enhances neuroplasticity. Notably, the effects were delayed: no change appeared on day one, but marked improvements emerged a week later. Treated mice learned from negative feedback and adapted to more complex environments, especially when the drug was paired with learning tasks. The findings suggest potential new treatments for psychiatric conditions such as depression and anxiety, which are often linked to impaired cognitive flexibility. However, results remain limited to mouse studies, and long-term effects in humans require rigorous validation.

Overview

A research team at Weill Cornell Medicine reports that a single dose of the synthetic psychedelic DOI (2,5-dimethoxy-4-iodoamphetamine) can induce long-term structural changes in the mouse brain and significantly boost cognitive flexibility. The study was published in *Nature Molecular Psychiatry*.

Key Findings

The compound: DOI is a synthetic psychedelic. Researcher Merima Šabanović found that one dose activates brain plasticity, prompting lasting neural reorganization.
Mechanism: The drug activates serotonin receptors and enhances the brain's "plasticity," reshaping neuronal networks.
Delayed effect: No changes were observed on the first day after injection; significant cognitive improvements appeared after one week.
Learning from failure: Treated mice began paying attention to negative feedback, allowing them to adapt to more complex environments.
Task-dependent benefit: The drug's effects are maximized when combined with learning challenges.

Potential Applications

Impaired cognitive flexibility is commonly associated with depression and anxiety. If DOI proves effective in humans, it could become a new tool for treating psychiatric disorders.

Caveats

The findings are limited to mouse experiments so far, and long-term effects still require rigorous validation. This article summarizes recent research and does not constitute medical advice.

*Source: Nature Molecular Psychiatry*